Condition: T-cell Lymphoma · T-cell Leukemia · Sponsor: Huda Salman
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
This description comes directly from the study's public registry record.
Tara Haney, RN · 317-2784184 · tnhaney@iu.edu
Huda Salman, MD · (317) 278-9504 · hsalman@iu.edu
Always discuss trial participation with your own doctor first.
| University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| Riley Hospital for Children | Indianapolis, Indiana, United States | Recruiting |
| Albert Einstein Health Network | New York, New York, United States | Recruiting |
| Stony Brook Cancer Center | Stony Brook, New York, United States | Active Not Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03829540